

In collaboration with The Oxford University Clinical Research Unit, Vietnam



# MONDAY 04 NOVEMBER 2024

Venue: Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

Time Activity

14.00 Tour of OUCRU Laboratory Facilities – Limited places: Confirmed Names Only

The programme is subject to change

oucru



Page 1 of 5



### **TUESDAY 05 NOVEMBER 2024**

Venue – Sheraton Hotel, Ho Chi Minh City, Vietnam

Time	Activity
08.30	Registration Chair: Dr Ankur Mutreja
09.00	<b>Welcome - Network Information</b> Professor Cal MacLennan, Director of BactiVac & Professor Adam Cunningham, Co-Director of BactiVac, UK
09.15	<b>BactiVac Network - Opening Address</b> Professor Peter Borriello, Trustee of Safe Medicines for Animals - regulatory training (SMArt), UK
09.30	<b>Oxford University Clinical Research Unit - Opening Address</b> Professor Guy Thwaites, Director, Oxford University Clinical Research Unit, Vietnam
09.45	Vaccines to Prevent Antimicrobial Resistance – Data from Three Phase 3 Typhoid Conjugate Vaccine Trials Dr James E. Meiring, Senior Clinical Lecturer, University of Liverpool and Malawi Liverpool Wellcome Trust Programme, UK/Malawi
10.15	<b>Development and Qualification of Immunoassays for Shigella Vaccines</b> Dr Paul W. Rhyne, Bioassay Lead, Gates Medical Research Institute, USA
10.45	Speed Networking Session
12.30	Lunch Chair: Prof Constantino López-Macías
13.30	<b>Technologies Available for Bacterial Vaccines</b> Dr Francesca Micoli, Senior Project Leader and Director of the Innovation Academy at GSK Vaccine Institute for Global Health, Italy
14.00	A tale of two enterics: Salmonella & Shigella Vaccines - Progress since 2017 Professor Cal MacLennan, Director of BactiVac, UK
14.30	<b>Combination Bacterial Vaccines</b> Professor Dr Annelies Wilder-Smith, Team Lead for Vaccine Development, World Health Organisation, Switzerland
15.00	Refreshments Chair: Dr Deborah King
15.30	Vaccine Clinical Trials, Recent Advancements, Challenges & Opportunities Dr Tarun Saluja, Head of Clinical Development, International Vaccine Institute, South Korea
16.00	<b>Oral Paratyphoid Vaccine Study in the Human Challenge Model</b> Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the University of Oxford and a Consultant Paediatrician at the Oxford Children's Hospital, UK
16.30	Klebsiella Pneumoniae in Vietnam: The Urgent Need for a Vaccine Dr Duy Pham, Head of Molecular Epidemiology Group, Oxford University Clinical Research Unit, Vietnam
17.00	Bangladesh Vaccine Therapeutics Diagnostics and Manufacturing and Regulatory Strengthening Ms Aastha Arora, Public Health Consultant, Asian Development Bank, Philippines

- 17.30 Close of day programme
- 19.00 Conference Dinner The Sheraton Hotel



Page 2 of 5



Venue – Sheraton Hotel, Ho Chi Minh City, Vietnam

### WEDNESDAY 06 NOVEMBER 2024

Time Activity

08.30	DCVMN in Pursuit for Excellence: A Journey of Innovations, Development, Manufacturing and Delivery of Bacterial Vaccines
	Mr Rajinder Kumar Suri, CEO, DCVMN International, India
09.00	Biological E's Longstanding Commitment of Bacterial Vaccine Development Dr Nupur Sengupta, General Manager, Global Alliance Management, Bio E-Vaccines, India
09.30	<b>The Group B Streptococcal Vaccine Pipeline</b> Professor Kirsty Le Doare, Professor of Vaccinology and Immunology, St. George's. University of London, UK
10.00	Standardization of Immune Assays for Characterizing Immune Responses to GBS Vaccines in Clinical Studies Dr Rama Raghunandan, Scientific Director, PATH, USA
10.30	Refreshments Chair: Dr Jeremy Salt
11.00	Encouraging the Use of Biological Products and Vaccines to Replace Antibiotics to Meet the Export Strategy of the Ministry of Agriculture and Rural Development Dr Dang Thi Thanh SON, Head of Veterinary Hygiene Department, National Institute for Veterinary Research (NIVR), Vietnam
11.30	<b>Reduction of Antibiotic Use in Tilapia Farming</b> Associate Professor Nguyen Ngoc Phuoc, Senior Lecturer, Faculty of Fishery, University of Agriculture and Forestry, Hue University, Vietnam
12.00	Streptococcus suis Infection in Human: A New Insight from Whole Genome Sequence Study Associate Professor Ngo Thi Hoa, Head of Zoonoses Group, Oxford University Clinical Research Unit, Vietnam
12.30	Lunch Chair: Prof Stephen Baker
13.30	Toward a multivalent synthetic oligosaccharide-based conjugate vaccine against Shigella: clinical findings from a monovalent prototype in Kenyan infants Dr Laurence A. Mulard, Research Director, INSTITUT PASTEUR, France
	bi Educence in manara, nescuren birector, morri or more ong manee

- 14.00 **BactiVac Network Opportunities** Dr Jo Dean, Operations Manager, BactiVac Network, UK
- 14.30 **Oral Presentations from Selected Poster Abstracts** See Appendix 1
- 16.00 **Poster Abstract Viewing**
- 18.00 Close of day programme

The programme is subject to change





Page 3 of 5



**Chair: Dr Seanette Wilson** 



THURS	SDAY 07 NOVEMBER 2024 Venue – Sheraton Hotel, Ho Chi Minh City, Vietnam	
Time	Activity Chair: Prof Alex Richter	
09.00	<b>The Challenge of Developing Vaccines against Human Adapted Pathogens</b> Professor Christoph Tang, Professor of Cellular Pathology, Sir William Dunn School of Pathology, UK	
09.30	Clinical Trials in Asia – Opportunities and Challenges Dr Evelyne Kestelyn, Head of the Clinical Trials Unit, Oxford University Clinical Research Unit, Vietnam	
10.00	<b>The Role of the Social Structure in Vaccine Hesitancy</b> Dr Ha Nguyen Thanh, Postdoctoral Researcher, Oxford University Clinical Research Unit, Vietnam	
10.30	Refreshments Chair: Dr Xin Tong	
11.00	<b>The Clinical Challenge of Acinetobacter baumannii and Potential New Therapeutic Approaches</b> Professor Jeremy Brown, Professor of Respiratory Infection, University College London, UK	
11.30	K-Vax: The Universal Vaccine for Prevention of Diseases by Klebsiella Pneumoniae Dr Aída Alonso-del Valle, Vaccine Development Manager, Vaxdyn, Spain	
12.00	<b>Perspective on the Success of Bacterial Vaccine Development and Manufacture in Asia</b> Dr Jerome Kim, Director General of the International Vaccine Institute, South Korea	
12.30	Group Photo	
12.45	Lunch Chair: Dr Alain Bouckenooghe	
14.00	Translational Workshop by Hilleman Laboratories What Does it Take to Move a Vaccine Through the First 'Valley of Death?'	
	<b>Welcome &amp; Opening</b> Dr Alain Bouckenooghe, Head of Research &Development, Hilleman Laboratories, Singapore	
14.05	Vaccine development: From Lab to Clinic Dr Pei-Yin Lim, Manager, Preclinical R&D, Hilleman Laboratories, Singapore	
14.30	<b>Building a Business Case</b> Dr N Erlyani Abd Hamid, Assistant Director, Business Strategy & Programme Management, Hilleman Laboratories, Singapore	
15.00	Rapid Approach to Vaccine Development with Case Study Kay Hunsberger, Executive Director, Merck Sharp & Dohme Inc., USA	
15.30	Refreshments	
16.00	Panel Session Q&A Session	
17.00	<b>Annual Network Meeting Closing Address</b> Professor Cal MacLennan, Director of BactiVac & Professor Adam Cunningham, Co-Director of BactiVac, UK	
The programme is subject to change		



Page 4 of 5





## **APPENDIX 1**

Venue – Sheraton Hotel, Ho Chi Minh City, Vietnam

### WEDNESDAY 06 NOVEMBER 2024

#### **Oral Presentations from Selected Poster Abstracts**

- 14.30 **Turbo: an adjuvant for bacterial polysaccharide vaccines** Dr Kishore R. Alugupalli, Chief Executive Officer, TurboVax Inc., USA
- 14.45 Safety and immunogenicity of a 4-component GMMA-based Shigella vaccine in healthy European adults: Stage 1 of a randomized, controlled phase I/II clinical trial Dr Ashwani Kumar Arora, Head Clinical Development & Regulatory Affairs, GSK Vaccines for Global Health, Italy
- 15.00 Exploring the role of pneumococcal conjugate vaccine (PCV)-13 and its mechanism against *Streptococcus* pneumoniae Dr Gift Chiwala, Postdoctoral Research Associate, Malawi Liverpool Wellcome Programme, Malawi
- 15.15 Comparative analysis of gonococcal antibody levels and function in sera from mice immunised with candidate native Outer Membrane Vesicle (nOMV) gonococcal vaccines and from patients convalescing from gonorrhoea *Ms Ilaria Onofrio, DPhil student, Jenner Institute, University of Oxford, UK*
- 15.30 Live vector-based multivalent vaccine approach against cecal colonization of *Campylobacter jejuni* in commercial chickens Dr Amirul Islam Mallick, Associate Professor, Indian Institute of Science Education and Research Kolkata, India
- 15.45 Preliminary analysis and outcomes from a first-in-human Nontyphoidal Salmonella controlled human infection model
  Dr. Christenhar Smith, Clinical Research Follow, Imparial Colloga, London, UK

Dr Christopher Smith, Clinical Research Fellow, Imperial College London, UK

The programme is subject to change



welkome Medical Research Council American

Page **5** of **5**